Vedolizumab and Ustekinumab Levels in Pregnant Women With Inflammatory Bowel Disease and Infants Exposed In Utero
Copyright © 2024 AGA Institute. All rights reserved..
BACKGROUND & AIMS: Vedolizumab and ustekinumab pharmacokinetics in pregnancy and the infant after in utero exposure remain incompletely defined. We aim to define the antenatal stability of ustekinumab and vedolizumab levels and the time at which infant drug levels become undetectable.
METHODS: This multicenter prospective observational cohort study recruited pregnant or preconception women with inflammatory bowel disease receiving vedolizumab or ustekinumab. Trough drug levels, clinical data, and biochemical data were documented preconception, during each trimester of pregnancy, and postpartum. Maternal and cord blood drug levels were measured at delivery and in infants until undetectable. Infant outcomes were assessed until 2 years of age.
RESULTS: A total of 102 participants (vedolizumab, n = 58) were included. The majority of mothers were, and remained, in clinical and biochemical remission. Maternal vedolizumab levels decreased over the course of pregnancy in association with increasing weight, rather than increasing gestation. Maternal ustekinumab levels remained stable. The median time to drug becoming undetectable in the infant was shorter for vedolizumab (11 wk; range, 5-19 wk; n = 32) than ustekinumab (14 wk; range, 9-36 wk; n = 17) and correlated positively with infant delivery level. Thirty-two of 41 (88%) and 17 of 30 (67%) vedolizumab- and ustekinumab-exposed infants had undetectable drug levels by 15 weeks of age, respectively. Pregnancy and infant outcomes were favorable. Twenty infants with undetectable drug levels received the rotavirus vaccine, with no adverse reactions reported.
CONCLUSIONS: Maternal vedolizumab levels decreased, whereas ustekinumab levels remained stable over the course of pregnancy. Most vedolizumab- and approximately half of ustekinumab-exposed infants had undetectable drug levels by 15 weeks of age. No concerning maternal or infant safety signals were identified.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association - (2024) vom: 15. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Prentice, Ralley [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Inflammatory Bowel Disease |
|---|
| Anmerkungen: |
Date Revised 13.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.cgh.2024.02.025 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369825837 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369825837 | ||
| 003 | DE-627 | ||
| 005 | 20240413232553.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240317s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cgh.2024.02.025 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1374.xml |
| 035 | |a (DE-627)NLM369825837 | ||
| 035 | |a (NLM)38492905 | ||
| 035 | |a (PII)S1542-3565(24)00252-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Prentice, Ralley |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Vedolizumab and Ustekinumab Levels in Pregnant Women With Inflammatory Bowel Disease and Infants Exposed In Utero |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 13.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 AGA Institute. All rights reserved. | ||
| 520 | |a BACKGROUND & AIMS: Vedolizumab and ustekinumab pharmacokinetics in pregnancy and the infant after in utero exposure remain incompletely defined. We aim to define the antenatal stability of ustekinumab and vedolizumab levels and the time at which infant drug levels become undetectable | ||
| 520 | |a METHODS: This multicenter prospective observational cohort study recruited pregnant or preconception women with inflammatory bowel disease receiving vedolizumab or ustekinumab. Trough drug levels, clinical data, and biochemical data were documented preconception, during each trimester of pregnancy, and postpartum. Maternal and cord blood drug levels were measured at delivery and in infants until undetectable. Infant outcomes were assessed until 2 years of age | ||
| 520 | |a RESULTS: A total of 102 participants (vedolizumab, n = 58) were included. The majority of mothers were, and remained, in clinical and biochemical remission. Maternal vedolizumab levels decreased over the course of pregnancy in association with increasing weight, rather than increasing gestation. Maternal ustekinumab levels remained stable. The median time to drug becoming undetectable in the infant was shorter for vedolizumab (11 wk; range, 5-19 wk; n = 32) than ustekinumab (14 wk; range, 9-36 wk; n = 17) and correlated positively with infant delivery level. Thirty-two of 41 (88%) and 17 of 30 (67%) vedolizumab- and ustekinumab-exposed infants had undetectable drug levels by 15 weeks of age, respectively. Pregnancy and infant outcomes were favorable. Twenty infants with undetectable drug levels received the rotavirus vaccine, with no adverse reactions reported | ||
| 520 | |a CONCLUSIONS: Maternal vedolizumab levels decreased, whereas ustekinumab levels remained stable over the course of pregnancy. Most vedolizumab- and approximately half of ustekinumab-exposed infants had undetectable drug levels by 15 weeks of age. No concerning maternal or infant safety signals were identified | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Inflammatory Bowel Disease | |
| 650 | 4 | |a Pregnancy | |
| 650 | 4 | |a Ustekinumab | |
| 650 | 4 | |a Vedolizumab | |
| 700 | 1 | |a Flanagan, Emma |e verfasserin |4 aut | |
| 700 | 1 | |a Wright, Emily K |e verfasserin |4 aut | |
| 700 | 1 | |a Gibson, Peter R |e verfasserin |4 aut | |
| 700 | 1 | |a Rosella, Sam |e verfasserin |4 aut | |
| 700 | 1 | |a Rosella, Ourania |e verfasserin |4 aut | |
| 700 | 1 | |a Begun, Jakob |e verfasserin |4 aut | |
| 700 | 1 | |a An, Yoon-Kyo |e verfasserin |4 aut | |
| 700 | 1 | |a Lawrance, Ian C |e verfasserin |4 aut | |
| 700 | 1 | |a Kamm, Michael A |e verfasserin |4 aut | |
| 700 | 1 | |a Sparrow, Miles |e verfasserin |4 aut | |
| 700 | 1 | |a Goldberg, Rimma |e verfasserin |4 aut | |
| 700 | 1 | |a Prideaux, Lani |e verfasserin |4 aut | |
| 700 | 1 | |a Vogrin, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Kiburg, Katerina V |e verfasserin |4 aut | |
| 700 | 1 | |a Ross, Alyson L |e verfasserin |4 aut | |
| 700 | 1 | |a Burns, Megan |e verfasserin |4 aut | |
| 700 | 1 | |a Bell, Sally J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association |d 2003 |g (2024) vom: 15. März |w (DE-627)NLM147178851 |x 1542-7714 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:15 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cgh.2024.02.025 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 15 |c 03 | ||